Phillips M
St. Vincent's Medical Center of Richmond, Department of Medicine, Staten Island, NY 10310.
Adv Alcohol Subst Abuse. 1987;7(1):51-61. doi: 10.1300/j251v07n01_05.
A pilot study of a new injectable sustained-release formulation of disulfiram was performed in two alcoholic volunteers. Both subjects were treated with a single subcutaneous dose of disulfiram (1g or 2g). An oral alcohol challenge (0.15g/kg) was administered before the disulfiram was injected, and similar posttreatment alcohol challenges were repeated on days 7, 14, 21, and 28. Subjects were observed at five minute intervals for a period of 90 minutes after all alcohol challenges. Subjective responses were monitored, as well as heart rate, blood pressure, skin temperature, and the concentration of ethanol and acetaldehyde in the breath. Persistent and statistically significant changes were observed in the subjective and objective responses to alcohol during the posttreatment period. These responses to the alcohol challenges were consistent with disulfiram-ethanol reactions resulting from the persistent pharmacologic effects of the parenteral sustained-release disulfiram.
对一种新的双硫仑注射用缓释制剂进行了一项有两名酒精成瘾志愿者参与的初步研究。两名受试者均接受了单次皮下注射双硫仑(1克或2克)治疗。在注射双硫仑之前给予口服酒精激发试验(0.15克/千克),并在第7、14、21和28天重复进行类似的治疗后酒精激发试验。在所有酒精激发试验后,每隔五分钟对受试者观察90分钟。监测主观反应以及心率、血压、皮肤温度和呼出气体中乙醇和乙醛的浓度。在治疗后期间,观察到对酒精的主观和客观反应出现持续且具有统计学意义的变化。这些对酒精激发试验的反应与肠胃外缓释双硫仑的持续药理作用导致的双硫仑 - 乙醇反应一致。